Researchers report the identification of a new target for the PARP inhibitor drug talazoparib and show that combination treatment with talazoparib and the WEE1 inhibitor adavosertib results in enhanced anti-cancer effects.
from Breast Cancer News -- ScienceDaily https://ift.tt/3fgDUXo
0 comments:
Post a Comment